Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome
- 4 January 2021
- journal article
- letter
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 41 (3) , 688-690
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Medical algorithm: Diagnosis and treatment of hypereosinophilic syndromeAllergy, 2020
- Benralizumab for PDGFRA -Negative Hypereosinophilic SyndromeNew England Journal of Medicine, 2019
- ADAPTAÇÃO TRANSCULTURAL E VALIDAÇÃO DA ESCALA DE GRAVIDADE DE PRURIDO EM CRIANÇAS E ADOLESCENTES COM DERMATITE ATÓPICARevista Paulista de Pediatria, 2017
- Validation study of a Portuguese version of the Hospital Anxiety and Depression ScalePsychology, Health & Medicine, 2007
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994